Quellenangaben zur Seite "Behandlung | Medikamentöse Theraphie"
Andersch S, Rosenberg NK, Kullingsjo H, Ottosson JO, Bech P, Bruun-Hansen J, Hanson L, Lorentzen K, Mellergard M, Rasmussen S, . Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatr.Scand.Suppl 1991; 365:18-27.
Baetz M, Bowen RC. Efficacy of divalproex sodium in patients with panic disorder and mood instability who have not responded to conventional therapy. Can.J.Psychiatry 1998; 43:73-77.
Bakker A, van Balkom AJ, Spinhoven P. SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr.Scand. 2002; 106:163-167.
Bakker A, van Balkom AJ, Stein DJ. Evidence-based pharmacotherapy of panic disorder. Int.J.Neuropsychopharmacol. 2005; 8:473-482.
Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J.Psychopharmacol. 2005; 19:567-596.
Bale JF, Jr., Kern ER, Overall JC, Jr., Glasgow LA. Enhanced susceptibility of mice infected with murine cytomegalovirus to intranasal challenge with Escherichia coli: pathogenesis and altered inflammatory response. J.Infect.Dis. 1982; 145:525-531.
Ballenger JC, Davidson JR, Lecrubier Y, Nutt DJ, Baldwin DS, den Boer JA, Kasper S, Shear MK. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J.Clin.Psychiatry 1998; 59 Suppl 8:47-54.
Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J.Biol.Psychiatry 2002; 3:171-199.
Beauclair L, Fontaine R, Annable L, Holobow N, Chouinard G. Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J.Clin.Psychopharmacol. 1994; 14:111-118.
Bertani A, Perna G, Migliarese G, Di Pasquale D, Cucchi M, Caldirola D, Bellodi L. Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsychiatry 2004; 37:206-210.
Bourin M, Lambert O. Pharmacotherapy of anxious disorders. Hum.Psychopharmacol. 2002; 17:383-400.
Buigues J, Vallejo J. Therapeutic response to phenelzine in patients with panic disorder and agoraphobia with panic attacks. J.Clin.Psychiatry 1987; 48:55-59.
Carli V, Sarchiapone M, Camardese G, Romano L, DeRisio S. Mirtazapine in the treatment of panic disorder. Arch.Gen.Psychiatry 2002; 59:661-662.
Cryan JF, O'Leary OF, Jin SH, Friedland JC, Ouyang M, Hirsch BR, Page ME, Dalvi A, Thomas SA, Lucki I. Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proc.Natl.Acad.Sci.U.S.A 2004; 101:8186-8191.
Dannon PN, Iancu I, Grunhaus L. The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study. Hum.Psychopharmacol. 2002; 17:329-333.
Evans M, Bradwejn J, Dunn L, eds. Anxiety Review Panel. Guidelines for the treatment of anxiety disorders in primary care. Toronto, Canada: Queen's Printer of Ontario, 2000.
Furukawa TA, Watanabe N, Churchill R. Psychotherapy plus antidepressant for panic disorder with or without agoraphobia: systematic review. Br.J.Psychiatry 2006; 188:305-312.
Gorman JM. The use of newer antidepressants for panic disorder. J.Clin.Psychiatry 1997; 58 Suppl 14:54-58.
Hirschmann S, Dannon PN, Iancu I, Dolberg OT, Zohar J, Grunhaus L. Pindolol augmentation in patients with treatment-resistant panic disorder: A double-blind, placebo-controlled trial. J.Clin.Psychopharmacol. 2000; 20:556-559.
Jonas JM, Cohon MS. A comparison of the safety and efficacy of alprazolam versus other agents in the treatment of anxiety, panic, and depression: a review of the literature. J.Clin.Psychiatry 1993; 54 Suppl:25-45.
Kern N, Ströhle A. Psychopharmakotherapie bei Angsterkrankungen. Psychotherapie 2003; 8:104-113.
Liebowitz MR. Antidepressants in panic disorders. Br.J.Psychiatry Suppl 1989;46-52.
Marks IM, Swinson RP, Basoglu M, Kuch K, Noshirvani H, O'Sullivan G, Lelliott PT, Kirby M, McNamee G, Sengun S, . Alprazolam and exposure alone and combined in panic disorder with agoraphobia. A controlled study in London and Toronto. Br.J.Psychiatry 1993; 162:776-787.
Mathew SJ, Coplan JD, Gorman JM. Management of treatment-refractory panic disorder. Psychopharmacol.Bull. 2001; 35:97-110.
Mitte K. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J.Affect.Disord. 2005; 88:27-45.
Mula M, Pini S, Cassano GB. The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence. J.Clin.Psychopharmacol. 2007; 27:263-272.
Munjack DJ, Crocker B, Cabe D, Brown R, Usigli R, Zulueta A, McManus M, McDowell D, Palmer R, Leonard M. Alprazolam, propranolol, and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J.Clin.Psychopharmacol. 1989; 9:22-27.
Nardi AE, Perna G. Clonazepam in the treatment of psychiatric disorders: an update. Int.Clin.Psychopharmacol. 2006; 21:131-142.
Noyes R, Jr., Garvey MJ, Cook B, Suelzer M. Controlled discontinuation of benzodiazepine treatment for patients with panic disorder. Am.J.Psychiatry 1991; 148:517-523.
Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, Taylor CB, Dager SR, Shiovitz T. Placebo-controlled study of gabapentin treatment of panic disorder. J.Clin.Psychopharmacol. 2000; 20:467-471.
Pollack M, Mangano R, Entsuah R, Tzanis E, Simon NM. A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology (Berl) 2007; 194:233-242.
Pollack MH, Worthington JJ, III, Otto MW, Maki KM, Smoller JW, Manfro GG, Rudolph R, Rosenbaum JF. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol.Bull. 1996; 32:667-670.
Primeau F, Fontaine R, Beauclair L. Valproic acid and panic disorder. Can.J.Psychiatry 1990; 35:248-250.
Ravaris CL, Friedman MJ, Hauri PJ, McHugo GJ. A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients. J.Clin.Psychopharmacol. 1991; 11:344-350.
Ribeiro L, Busnello JV, Kauer-Sant'Anna M, Madruga M, Quevedo J, Busnello EA, Kapczinski F. Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz.J.Med.Biol.Res. 2001; 34:1303-1307.
Sarchiapone M, Amore M, De Risio S, Carli V, Faia V, Poterzio F, Balista C, Camardese G, Ferrari G. Mirtazapine in the treatment of panic disorder: an open-label trial. Int.Clin.Psychopharmacol. 2003; 18:35-38.
Seedat S, van Rheede vO, Muller JE, Mohr N, Stein DJ. Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. Int.Clin.Psychopharmacol. 2003; 18:279-284.
Sepede G, De Berardis D, Gambi F, Campanella D, La Rovere R, D'Amico M, Cicconetti A, Penna L, Peca S, Carano A, Mancini E, Salerno RM, Ferro FM. Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J.Clin.Psychopharmacol. 2006; 26:45-49.
Sheehan DV, Ballenger J, Jacobsen G. Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch.Gen.Psychiatry 1980; 37:51-59.
Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, Savino M. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J.Clin.Psychiatry 2002; 63:31-37.
Woodman CL, Noyes R, Jr. Panic disorder: treatment with valproate. J.Clin.Psychiatry 1994; 55:134-136.
Druckansicht